Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | May 06, 2026 | May 08, 2026 |
| Aptiv PLCAPTV · Entity 3559 | Director | August 05, 2026 | August 06, 2026 |
| Hims & Hers Health, Inc.OAC · Entity 1878 | Director | July 17, 2019 | July 18, 2019 |
| LKQ CORPLKQ · Entity 1128 | Director | May 08, 2017 | May 10, 2017 |
| Light & Wonder, Inc.SGMS · Entity 9758 | Director | June 10, 2020 | June 12, 2020 |
| Oaktree Acquisition Corp. IIOACB · Entity 142657 | Director | September 16, 2020 | September 16, 2020 |
| Oaktree Acquisition Corp. III Life SciencesOACC · Entity 6078 | Director | October 23, 2024 | October 24, 2024 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 02, 2026 | January 15, 2026 |
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Director | January 05, 2007 | January 09, 2007 |
| Telesis Bio Inc.TBIO · Entity 15606 | Director · 10% owner | June 06, 2023 | June 08, 2023 |
| Versigent PLCVGNT · Entity 4179 | Director | September 18, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 832,800 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Exercise / conversion · Acquired 48,747 · Balance 832,800 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-07 · Exercise / conversion · Disposed 48,747 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: On May 6, 2025, the reporting person was granted 48,747 restricted stock units vesting on May 7, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 30,837 |
Reported balance
After 2026-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-06 · Grant · Acquired 30,837 · Balance 30,837 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: On May 6, 2025, the reporting person was granted 48,747 restricted stock units vesting on May 7, 2026.
F3: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
Aptiv PLC
Report date August 05, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectWoburn Abbey March 2021 Trust GST Exempt Share | 105,631 |
Reported balance
After 2026-08-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-05 · Purchase · Acquired 105,631 · Balance 105,631 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 13,612 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,612 |
| Ordinary SharesSEC Table I · non-derivative | IndirectPaul M. Meister 2005 Revocable Trust | 19,181 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 19,181 |
Hims & Hers Health, Inc.
Report date July 17, 2019 · Filed July 18, 2019
This filing explicitly reported no securities owned.
LKQ CORP
Report date May 08, 2017 · Filed May 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,067 |
Reported balance
After 2017-05-08 transaction · row 1
1 source rowRow 1 · 2017-05-08 · Grant · Acquired 3,662 · Balance 272,067 F1: The transaction represents an award of restricted stock units that vest with respect to 100% of the number of shares subject to the award on the earlier of (a) the one-year anniversary of the grant date, and (b) the date of the 2018 Annual Meeting of Stockholders of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction represents an award of restricted stock units that vest with respect to 100% of the number of shares subject to the award on the earlier of (a) the one-year anniversary of the grant date, and (b) the date of the 2018 Annual Meeting of Stockholders of the Issuer.
Light & Wonder, Inc.
Report date June 10, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,740 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Exercise / conversion · Acquired 25,622 · Balance 82,740 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-10 · Exercise / conversion · Disposed 7,710 · Balance 0 F1: Represents vesting of restricted stock units granted on June 12, 2019 in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-10 · Exercise / conversion · Disposed 2,091 · Balance 0 F2: Represents vesting of the remaining restricted stock units granted on June 13, 2018 in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-10 · Exercise / conversion · Disposed 4,339 · Balance 0 F3: Represents vesting of the remaining restricted stock units granted on June 15, 2016 in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-10 · Exercise / conversion · Disposed 3,110 · Balance 0 F4: Represents vesting of the remaining restricted stock units granted on June 19, 2017 in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,372 |
Reported balance
After 2020-06-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-06-10 · Grant · Acquired 8,372 · Balance 8,372 F5: The restricted stock units will vest immediately in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. Each unit converts into a share of common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-06-10 · Exercise / conversion · Disposed 8,372 · Balance 0 F6: Represents vesting of restricted stock units granted on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of restricted stock units granted on June 12, 2019 in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.
F2: Represents vesting of the remaining restricted stock units granted on June 13, 2018 in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.
F3: Represents vesting of the remaining restricted stock units granted on June 15, 2016 in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.
F4: Represents vesting of the remaining restricted stock units granted on June 19, 2017 in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.
F5: The restricted stock units will vest immediately in connection with the conclusion of Mr. Meister's service as a director on June 10, 2020. Each unit converts into a share of common stock on a one-for-one basis.
F6: Represents vesting of restricted stock units granted on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.
Oaktree Acquisition Corp. II
Report date September 16, 2020 · Filed September 16, 2020
This filing explicitly reported no securities owned.
Oaktree Acquisition Corp. III Life Sciences
Report date October 23, 2024 · Filed October 24, 2024
This filing explicitly reported no securities owned.
Quanterix Corp
Report date January 02, 2026 · Filed January 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 313,253 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 3,974 · Balance 313,253 F1: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third and fourth quarter of 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third and fourth quarter of 2025.
THERMO FISHER SCIENTIFIC INC.
Report date January 05, 2007 · Filed January 09, 2007
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 350,000 |
Ending reported balance
After 2007-01-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2007-01-05 · Sale · Disposed 175,000 · Balance 450,000 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. F2: The sales price shown is the average sales price for all shares sold on January 5, 2007, actual denominations are as follows: 900 shares at $44.95; 800 shares at $44.96; 600 shares at $44.97; 21,300 shares at $45.00; 6,100 shares at $45.01; 1,800 shares at $45.02; 15,300 shares at $45.05; 400 shares at $45.06; 2,400 shares at $45.07; 6,600 shares at $45.08; 300 shares at $45.09; 77,300 shares at $45.50; 200 shares at $45.52; 200 shares at $45.53; 36,300 shares at $45.55; 3,500 shares at $45.56; 600 shares at $45.58; and 400 shares at $45.59. Row 2 · 2007-01-08 · Sale · Disposed 100,000 · Balance 350,000 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. F3: The sales price shown is the average sales price for all shares sold on January 8, 2007, actual denominations are as follows: 12,400 shares at $44.90; 1,400 shares at $44.91; 2,800 shares at $44.92; 15,500 shares at $44.93; 500 shares at $44.94; 40,800 shares at $44.95; 1,900 shares at $44.97; 4,700 shares at $45.00; and 20,000 shares at $45.10. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006.
F2: The sales price shown is the average sales price for all shares sold on January 5, 2007, actual denominations are as follows: 900 shares at $44.95; 800 shares at $44.96; 600 shares at $44.97; 21,300 shares at $45.00; 6,100 shares at $45.01; 1,800 shares at $45.02; 15,300 shares at $45.05; 400 shares at $45.06; 2,400 shares at $45.07; 6,600 shares at $45.08; 300 shares at $45.09; 77,300 shares at $45.50; 200 shares at $45.52; 200 shares at $45.53; 36,300 shares at $45.55; 3,500 shares at $45.56; 600 shares at $45.58; and 400 shares at $45.59.
F3: The sales price shown is the average sales price for all shares sold on January 8, 2007, actual denominations are as follows: 12,400 shares at $44.90; 1,400 shares at $44.91; 2,800 shares at $44.92; 15,500 shares at $44.93; 500 shares at $44.94; 40,800 shares at $44.95; 1,900 shares at $44.97; 4,700 shares at $45.00; and 20,000 shares at $45.10.
Telesis Bio Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 108,270 |
Reported balance
After 2023-06-06 transaction · row 1
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 108,270 · Balance 108,270 F1: Represents a grant of restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2033-06-06 | Direct | 162,406 |
Reported balance
After 2023-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-06 · Grant · Acquired 162,406 · Balance 162,406 F2: The options vest in equal monthly installments over a three-year period from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units.
F2: The options vest in equal monthly installments over a three-year period from the grant date.
Versigent PLC
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 14.65 |
Reported balance
After 2026-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-18 · Grant · Acquired 14.65 · Balance 14.65 F1: The dividend equivalent rights accrued on grants of restricted stock units as a result of a dividend declared and paid by the issuer. These rights vest on the same schedule as the restricted stock units to which they relate. Each dividend equivalent right is the economic equivalent of one share of the issuer's ordinary shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The dividend equivalent rights accrued on grants of restricted stock units as a result of a dividend declared and paid by the issuer. These rights vest on the same schedule as the restricted stock units to which they relate. Each dividend equivalent right is the economic equivalent of one share of the issuer's ordinary shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 22, 2026 20:03 UTC | Versigent PLC VGNT · Entity 4179 | GrantDividend Equivalent Rights · Derivative | 14.65 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-397877 · ownership.xml · derivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14.65 Underlying: Ordinary Shares · 14.65 shares Expires not disclosed F1 · derivative.exercise_price: The dividend equivalent rights accrued on grants of restricted stock units as a result of a dividend declared and paid by the issuer. These rights vest on the same schedule as the restricted stock units to which they relate. Each dividend equivalent right is the economic equivalent of one share of the issuer's ordinary shares. F1 · derivative.exercise_date: The dividend equivalent rights accrued on grants of restricted stock units as a result of a dividend declared and paid by the issuer. These rights vest on the same schedule as the restricted stock units to which they relate. Each dividend equivalent right is the economic equivalent of one share of the issuer's ordinary shares. F1 · derivative.expiration_date: The dividend equivalent rights accrued on grants of restricted stock units as a result of a dividend declared and paid by the issuer. These rights vest on the same schedule as the restricted stock units to which they relate. Each dividend equivalent right is the economic equivalent of one share of the issuer's ordinary shares. Read SEC document |
| August 05, 2026 Filed Aug 6, 2026 20:05 UTC | Aptiv PLC APTV · Entity 3559 | PurchaseOrdinary Shares | 105,631 | $47.33 | $4,999,958.88 |
DisclosureSEC source: 0001193125-26-337965 · ownership.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Woburn Abbey March 2021 Trust GST Exempt Share Disclosed balance after: 105,631 Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 48,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032907 · wk-form4_1778271772.xml · derivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 48,747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 6, 2025, the reporting person was granted 48,747 restricted stock units vesting on May 7, 2026. F2 · derivative.expiration_date: On May 6, 2025, the reporting person was granted 48,747 restricted stock units vesting on May 7, 2026. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 48,747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-032907 · wk-form4_1778271772.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 832,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2026 Filed May 8, 2026 20:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 30,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032907 · wk-form4_1778271772.xml · derivative · entry 3 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,837 Underlying: Class A Common Stock · 30,837 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 20:04 UTC | Aptiv PLC APTV · Entity 3559 | GrantOrdinary Shares | 6,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-197157 · ownership.xml · nonDerivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,612 F3 · price: The Reporting Person has received restricted stock units that each represent a right to receive one ordinary share of the Issuer pursuant to the Issuer's Long Term Incentive Plan and will vest in full one day before the Issuer's Annual Meeting of Shareholders in 2027. F2 · balance_after: Total reflects adjustment of outstanding awards as a result of the spin-off of Versigent PLC. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 20:04 UTC | Aptiv PLC APTV · Entity 3559 | Tax withholdingOrdinary Shares | 590 | $59.12 | $34,880.80 |
DisclosureSEC source: 0001193125-26-197157 · ownership.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,268 F1 · price: Shares withheld to pay tax liabilities incident to the vesting of restricted stock units. F2 · balance_after: Total reflects adjustment of outstanding awards as a result of the spin-off of Versigent PLC. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:06 UTC | Versigent PLC VGNT · Entity 4179 | GrantOrdinary Shares | 5,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-177156 · ownership.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,561 F1 · balance_after: On April 1, 2026, Aptiv PLC ("Aptiv") completed a distribution of all of the ordinary shares, par value $0.01 per share, of the Issuer ("Issuer Ordinary Shares") to holders of ordinary shares of Aptiv on a pro rata basis (the "Distribution"). This amount includes 6,393 Issuer Ordinary Shares received by the Reporting Person in connection with the Distribution. Read SEC document |
| January 02, 2026 Filed Jan 15, 2026 18:56 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 3,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001033876-26-000001 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,253 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third and fourth quarter of 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:39 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,242 | $6.69 | $14,998.98 |
DisclosureSEC source: 0001562180-25-005256 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,279 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2025. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2025. F3 · balance_after: Includes 7,435 restricted stock units. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:04 UTC | Aptiv PLC APTV · Entity 3559 | GiftOrdinary Shares | 19,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-072561 · ownership.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,941 Read SEC document |
| May 06, 2025 Filed May 8, 2025 22:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 48,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023985 · wk-form4_1746744829.xml · derivative · entry 3 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,747 Underlying: Class A Common Stock · 48,747 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 05, 2025 Filed May 8, 2025 22:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 56,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023985 · wk-form4_1746744829.xml · derivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 56,361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 2, 2024, the reporting person was granted 56,361 restricted stock units vesting on May 5, 2025. F2 · derivative.expiration_date: On May 2, 2024, the reporting person was granted 56,361 restricted stock units vesting on May 5, 2025. Read SEC document |
| May 05, 2025 Filed May 8, 2025 22:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 56,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-023985 · wk-form4_1746744829.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| April 23, 2025 Filed Apr 24, 2025 20:08 UTC | Aptiv PLC APTV · Entity 3559 | GrantOrdinary Shares | 6,941 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-058021 · ownership.xml · nonDerivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,122 F2 · price: The Reporting Person has received restricted stock units that each represent a right to receive one ordinary share of the Issuer pursuant to the Issuer's Long Term Incentive Plan and will vest in full one day before the Issuer's Annual Meeting of Shareholders in 2026. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 20:08 UTC | Aptiv PLC APTV · Entity 3559 | Tax withholdingOrdinary Shares | 231 | $52.28 | $12,076.68 |
DisclosureSEC source: 0000950170-25-058021 · ownership.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,181 F1 · price: Shares withheld to pay tax liabilities incident to the vesting of restricted stock units. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:14 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,479 | $6.67 | $16,522.54 |
DisclosureSEC source: 0001562180-25-002981 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,037 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the first quarter of 2025. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on April 1, 2025. F3 · balance_after: Includes 7,435 restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:45 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Options (Right to buy) · Derivative | 15,821 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001562180-25-000201 · primarydocument.xml · derivative · entry 3 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,821 Underlying: Common Stock · 15,821 shares Expires 2035-01-02 F5 · shares: Represents non-qualified stock option to purchase 15,821 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:45 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 1,394 | $10.76 | $14,999.44 |
DisclosureSEC source: 0001562180-25-000201 · primarydocument.xml · nonDerivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,558 F3 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2024. F4 · price: Closing price of the Company's common stock on the Nasdaq Global Market on January 1, 2025. F2 · balance_after: Includes 7,435 restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:45 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 7,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000201 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,164 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2025 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 7,435 restricted stock units. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:06 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 1,200 | $12.50 | $15,000.00 |
DisclosureSEC source: 0001562180-24-007132 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,729 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2024. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2024. F3 · balance_after: Includes 2,947 restricted stock units. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 21:41 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 1,182 | $12.68 | $14,987.76 |
DisclosureSEC source: 0001562180-24-005537 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,529 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2024. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2024. F3 · balance_after: Includes 2,947 restricted stock units. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:44 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 107,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-023256 · wk-form4_1715719430.xml · derivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 107,034 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 9, 2023 the reporting person was granted 107,034 restricted stock units vesting on May 10, 2024. F2 · derivative.expiration_date: On May 9, 2023 the reporting person was granted 107,034 restricted stock units vesting on May 10, 2024. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:44 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 107,034 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023256 · wk-form4_1715719430.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 727,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 02, 2024 Filed May 6, 2024 21:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 56,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020711 · wk-form4_1715029887.xml · derivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,361 Underlying: Class A Common Stock · 56,361 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| April 25, 2024 Filed Apr 25, 2024 20:05 UTC | Aptiv PLC APTV · Entity 3559 | GrantOrdinary Shares | 5,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-048283 · ownership.xml · nonDerivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,412 F2 · price: The Reporting Person has received restricted stock units that each represent a right to receive one ordinary share of the Issuer pursuant to the Issuer's Long Term Incentive Plan and will vest in full one day before the Issuer's Annual Meeting of Shareholders in 2025. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:05 UTC | Aptiv PLC APTV · Entity 3559 | Tax withholdingOrdinary Shares | 337 | $70.25 | $23,674.25 |
DisclosureSEC source: 0000950170-24-048283 · ownership.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,229 F1 · price: Shares withheld to pay tax liabilities incident to the vesting of restricted stock units. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:04 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 630 | $23.78 | $14,981.40 |
DisclosureSEC source: 0001562180-24-003239 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,347 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the first quarter of 2024. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on April 1, 2024. F3 · balance_after: Includes 2,947 restricted stock units. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 6,412 | $0.00 Strike: $27.15 | $0.00 |
DisclosureSEC source: 0001562180-24-000230 · primarydocument.xml · derivative · entry 3 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,412 Underlying: Common Stock · 6,412 shares Expires 2034-01-02 F5 · shares: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 552 | $27.15 | $14,986.80 |
DisclosureSEC source: 0001562180-24-000230 · primarydocument.xml · nonDerivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,717 F3 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2023. F4 · price: Closing price of the Company's common stock on the Nasdaq Global Market on January 2, 2024. F2 · balance_after: Includes 2,947 restricted stock units. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000230 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,165 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,947 restricted stock units. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:02 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 561 | $26.71 | $14,984.31 |
DisclosureSEC source: 0001562180-23-007194 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,218 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2023. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 2, 2023. F3 · balance_after: Includes 8,083 restricted stock units. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:14 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 687 | $21.82 | $14,990.34 |
DisclosureSEC source: 0001562180-23-005692 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,657 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2023. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 3, 2023. F3 · balance_after: Includes 8,083 restricted stock units. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:25 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Options (Right to buy) · Derivative | 23,335 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001562180-23-004981 · primarydocument.xml · derivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,335 shares Expires 2023-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:25 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 23,335 | $2.89 | $67,438.15 |
DisclosureSEC source: 0001562180-23-004981 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 8,083 restricted stock units. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:12 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantStock Option (Right to Buy) · Derivative | 162,406 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0000899243-23-014946 · doc4.xml · derivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,406 Underlying: Common Stock · 162,406 shares Expires 2033-06-06 F2 · derivative.exercise_date: The options vest in equal monthly installments over a three-year period from the grant date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:12 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantCommon Stock | 108,270 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014946 · doc4.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,270 F1 · kind: Represents a grant of restricted stock units. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 112,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028730 · doc4.xml · derivative · entry 3 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 112,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On May 9, 2022 the reporting person was granted 112,179 restricted stock units vesting on May 10, 2023. F3 · derivative.expiration_date: On May 9, 2022 the reporting person was granted 112,179 restricted stock units vesting on May 10, 2023. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 112,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028730 · doc4.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 107,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028730 · doc4.xml · derivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,034 Underlying: Class A Common Stock · 107,034 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| April 26, 2023 Filed Apr 27, 2023 20:18 UTC | Aptiv PLC APTV · Entity 3559 | GrantOrdinary Shares | 3,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025852 · doc4.xml · nonDerivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,566 F2 · price: The Reporting Person has received restricted stock units that each represent a right to receive one ordinary share of the Issuer pursuant to the Issuer's Long Term Incentive Plan and will vest in full one day before the Issuer's Annual Meeting of Shareholders in 2024. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 20:18 UTC | Aptiv PLC APTV · Entity 3559 | Tax withholdingOrdinary Shares | 394 | $102.32 | $40,314.08 |
DisclosureSEC source: 0001209191-23-025852 · doc4.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,968 F1 · price: Shares withheld to pay tax liabilities incident to the vesting of restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 1,344 | $11.16 | $14,999.04 |
DisclosureSEC source: 0001562180-23-003368 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,635 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the first quarter of 2023. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on April 3, 2023. F3 · balance_after: Includes 8,083 restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:03 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 12,124 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001562180-23-000097 · primarydocument.xml · derivative · entry 3 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,124 Underlying: Common Stock · 12,124 shares Expires 2033-01-03 F5 · shares: Represents non-qualified stock option to purchase 12,124 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:03 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 1,166 | $12.86 | $14,994.76 |
DisclosureSEC source: 0001562180-23-000097 · primarydocument.xml · nonDerivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,291 F3 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2022. F4 · price: Closing price of the Company's common stock on the Nasdaq Global Market on January 3, 2023. F2 · balance_after: Includes 8,083 restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:03 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 8,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000097 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,125 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2023 granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 8,083 restricted stock units. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:05 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 1,431 | $10.48 | $14,996.88 |
DisclosureSEC source: 0001562180-22-007046 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,042 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2022. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 3, 2022. F3 · balance_after: Includes 2,688 restricted stock units. Read SEC document |
| August 10, 2022 Filed Aug 10, 2022 22:22 UTC | Quanterix Corp QTRX · Entity 6649 | PurchaseCommon Stock | 47,957 | $8.61 | $412,780.29 |
DisclosureSEC source: 0001562180-22-006033 · primarydocument.xml · nonDerivative · entry 2 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,611 F3 · price: This transaction was executed in multiple trades at prices ranging from $8.58 to $8.75. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 2,668 restricted stock units. Read SEC document |
| August 10, 2022 Filed Aug 10, 2022 22:22 UTC | Quanterix Corp QTRX · Entity 6649 | PurchaseCommon Stock | 186,347 | $8.51 | $1,585,533.45 |
DisclosureSEC source: 0001562180-22-006033 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,654 F1 · price: This transaction was executed in multiple trades at prices ranging from $7.58 to $8.57. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 2,668 restricted stock units. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:07 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 893 | $16.79 | $14,993.47 |
DisclosureSEC source: 0001562180-22-005561 · primarydocument.xml · nonDerivative · entry 1 MEISTER PAUL M · CIK 0001033876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,307 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2022. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2022. F3 · balance_after: Includes 2,668 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.